Dementia affects an estimated 46.8 million persons worldwide and is projected to affect approximately 131.5 million in 2050 with an estimated cost of US $818 billion in 2015 and US $2 trillion by 2050.
1 Current pharmaceutical approaches targeting neuropathologic processes such as Alzheimer disease (AD) offer limited benefit with symptom-modifying effects at best.
2 Switching to a preventive strategy through reduction of risk factors may be more beneficial than pharmacologic therapy after clinical expression of neuropathologic changes
3 and may lead to significant reductions in medical costs.
4